Profund Advisors LLC Acquires New Stake in Septerna, Inc. $SEPN

Profund Advisors LLC acquired a new position in shares of Septerna, Inc. (NASDAQ:SEPN) in the third quarter, Holdings Channel reports. The fund acquired 38,262 shares of the company’s stock, valued at approximately $1,497,000.

Several other hedge funds and other institutional investors also recently modified their holdings of the stock. Renaissance Technologies LLC acquired a new position in shares of Septerna in the first quarter valued at approximately $906,000. TRV GP V LLC purchased a new stake in shares of Septerna during the second quarter worth approximately $208,160,143. VIRGINIA RETIREMENT SYSTEMS ET Al acquired a new stake in shares of Septerna during the second quarter worth $445,000. First Light Asset Management LLC lifted its holdings in shares of Septerna by 31.4% during the second quarter. First Light Asset Management LLC now owns 963,260 shares of the company’s stock worth $32,260,000 after purchasing an additional 230,400 shares during the period. Finally, TRV GP VI LLC acquired a new stake in shares of Septerna during the second quarter worth $141,048,460.

Analysts Set New Price Targets

A number of research firms recently weighed in on SEPN. Wells Fargo & Company lifted their price objective on shares of Septerna from $48.00 to $50.00 and gave the company an “overweight” rating in a research report on Wednesday, August 12th. HC Wainwright upped their price objective on shares of Septerna from $40.00 to $60.00 and gave the stock a “buy” rating in a research report on Wednesday, August 12th. Guggenheim raised their target price on shares of Septerna from $45.00 to $51.00 and gave the stock a “buy” rating in a research note on Tuesday, August 11th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Septerna in a report on Thursday, October 15th. Finally, Raymond James Financial reiterated a “strong-buy” rating and set a $49.00 price target on shares of Septerna in a research note on Tuesday, August 11th. One analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $52.44.

Insider Buying and Selling at Septerna

In other Septerna news, SVP Daniel Long sold 3,333 shares of the firm’s stock in a transaction on Tuesday, September 1st. The stock was sold at an average price of $37.83, for a total value of $126,087.39. Following the completion of the sale, the senior vice president owned 96,412 shares of the company’s stock, valued at approximately $3,647,265.96. This trade represents a 3.34% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, COO Elizabeth Bhatt sold 25,000 shares of the firm’s stock in a transaction on Tuesday, August 11th. The shares were sold at an average price of $44.00, for a total value of $1,100,000.00. Following the completion of the sale, the chief operating officer directly owned 174,209 shares of the company’s stock, valued at approximately $7,665,196. This trade represents a 12.55% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 32,333 shares of company stock valued at $1,375,727 in the last quarter. 5.80% of the stock is currently owned by company insiders.

Septerna Trading Down 1.8%

Shares of SEPN stock opened at $43.20 on Tuesday. The company has a market cap of $2.02 billion, a price-to-earnings ratio of -80.00 and a beta of 2.29. The stock has a 50 day simple moving average of $39.02 and a 200-day simple moving average of $32.19. Septerna, Inc. has a 12-month low of $17.55 and a 12-month high of $51.10.

Septerna (NASDAQ:SEPN) last posted its quarterly earnings results on Monday, August 10th. The company reported ($0.29) EPS for the quarter, beating the consensus estimate of ($0.43) by $0.14. Septerna had a negative return on equity of 9.57% and a negative net margin of 24.51%. The business had revenue of $26.75 million during the quarter, compared to analysts’ expectations of $19.22 million. On average, equities analysts forecast that Septerna, Inc. will post -1.41 earnings per share for the current fiscal year.

Septerna Profile

Septerna, Inc is a clinical-stage biotechnology company focused on discovering and developing oral small-molecule medicines that target G protein-coupled receptors (GPCRs). GPCRs are a large class of cell-surface proteins involved in a wide range of biological processes and represent an important source of potential drug targets.

The company’s research is powered by its Native State platform, which is designed to study GPCRs in their natural biological configuration and support the discovery of selective small-molecule compounds.